

AMENDMENTS TO THE CLAIMS

Please amend Claim 45 as indicated below.

1-44. (Cancelled)

45. (Currently amended) A method for raising a specific T-cell response against an epitope of ML-IAP (SEQ ID NO:1) in an individual, said method comprising the steps of administering to the individual a polypeptide capable of raising a specific T-cell response, said polypeptide comprising a peptide selected from the group consisting of: RLQEERTCK (SEQ ID NO:245), RLQEERTCKV {SEQ ID NO:297}, QLCPICRAPV (SEQ ID NO:298), and VLEPPGARDV (SEQ ID NO:301); wherein said polypeptide comprises at the most 15 [[ammo]]amino acids, and raising a specific T-cell response against an epitope of ML-IAP in the individual.

46-53. (Cancelled)

54. (Previously presented) The method of Claim 45, wherein said polypeptide comprises the peptide RLQEERTCK (SEQ ID NO: 245).

55. (Previously presented) The method of Claim 45, wherein said polypeptide comprises the peptide RLQEERTCKV (SEQ ID NO: 297).

56. (Previously presented) The method of Claim 45, wherein said polypeptide comprises the peptide QLCPICRAPV (SEQ ID NO: 298).

57. (Previously presented) The method of Claim 45, wherein said polypeptide comprises the peptide VLEPPGARDV (SEQ ID NO: 301).

58. (Previously presented) The method of Claim 45, further comprising administering an adjuvant to the individual.

59. (Previously presented) The method of Claim 45, wherein the adjuvant is Montanide IAS-51 or QS-21.

60-65. (Cancelled)

66. (Previously presented) The method of Claim 45, wherein said administering comprises administering to said individual at least one peptide capable of binding an HLA molecule expressed in the individual.

67. **(Previously presented)** The method of Claim 45, wherein the individual has at least one of tissue type HLA-A2 and HLA-A3.